Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01067807 · ClinicalTrials.gov registry record · Phase 1
Proellex Pharmacokinetics Bridging Study
A Phase 1 study, sponsored by Repros Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT01067807 is a Phase 1 study that has completed, run by Repros Therapeutics. The registered enrollment target is 21 participants.
The verdict
NCT01067807, a Phase 1 study, has completed, sponsored by Repros Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
Healthy female subjects received a single dose of four different types of Proellex, the original 25 mg dose and three new formulations
Interventions
- DRUG 25 mg Proellex
- DRUG 50 mg Proellex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2007-06 |
| Est. Completion | 2007-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01067807
The ClinicalTrials.gov registry entry for NCT01067807 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Repros Therapeutics, which has 50 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 25 mg Proellex is the first listed.
NCT01067807 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01067807 about?
NCT01067807 is a clinical study titled "Proellex Pharmacokinetics Bridging Study". Healthy female subjects received a single dose of four different types of Proellex, the original 25 mg dose and three new formulations
What is the current status of trial NCT01067807?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2007-06. Estimated completion is 2007-07.
What interventions are being tested in trial NCT01067807?
The interventions under investigation include: 25 mg Proellex (DRUG), 50 mg Proellex (DRUG).
Who is sponsoring clinical trial NCT01067807?
This trial is sponsored by Repros Therapeutics, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.